Strong Buy
Average AnalystStrong Buy
Top AnalystNeutral
Stock Target AdvisorStrong Buy
Average UserUSD 28.45
-1.18 (-3.98)%
USD 3.87B
0.83M
USD 38.13(+34.03%)
Symbol | Name | Exchange | DNLI's Weight | Expense Ratio | Price(Change) | Market Cap |
---|---|---|---|---|---|---|
|
ALPS Medical Breakthrough.. | NYE | 2.50 % | 0.50 % | -1.18 (-2.93%) | USD0.13B |
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
The stock is trading high compared to its peers median on a price to book value basis.
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
The company had negative total cash flow in the most recent four quarters.
The company had negative total free cash flow in the most recent four quarters.
This stock has shown below median earnings growth in the previous 5 years compared to its sector